Entera Bio ENTX 深 滬
等待開盤 08-01 09:30:00 美东时间
2.99
+0.040
+1.36%
華盛通- 最 高3.20
- 今 開2.95
- 成交量 105.83万股
- 最 低 2.92
- 昨 收 2.95
- 總市值 1.47亿
- 52周最高 4.20
- 市盈率 靜 --
- 換手率 2.15%
- 52周最低 0.91
- 委 比 -72.15%
- 總股本 4929.02万
- 歷史最高 10.16
- 量 比 0.06
- 振 幅 9.49%
- 歷史最低 0.472
- 每 手 1
- 風險率 0.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | QBTS飙升20%，与AT&T达成量子计算合作；奥麦罗制药劲升15%，阿斯利康竞品药物3期临床试验失败
QBTS飙升20%，与AT&T达成量子计算合作；奥麦罗制药劲升15%，阿斯利康竞品药物3期临床试验失败；BMNR大涨13%，旗下以太坊价值已超公司原本市值>>
07-28 18:45
Entera Bio prices $275M private placement
Entera Bio (NASDAQ:ENTX) said on Monday it priced an oversubscribed $275M private placement led by existing investor BVF Partners, with participation from several healthcare-focused institutional inve...
07-27 20:59
Entera Bio Enters Into Securities Purchase Agreement For Oversubscribed Private Placement Financing, Expected To Result In Aggregate Gross Proceeds Of ~$275M
Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral PTH(1-34) peptide tablet in development for the treatment of osteoporosis TEL AVIV, July 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASD...
07-27 20:33
Entera Bio Expands Share Authorization and Equity Plans
Entera Bio ( ($ENTX) ) has issued an announcement. At its 2026 Annual Meeting o...
07-17 17:15
Reported Earlier: Entera Bio Receives FDA's Positive Feedback For Its Phase 3 Registrational Protocol For EB613 Tablet In Development To Treat Osteoporosis
Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that it has received positive feedback from the U.S. Food and Drug Administration (FDA) on its Phase 3 registrational protocol for EB613 (oral PTH(1-34), teriparatide), the first...
06-23 00:32
Entera Bio Presents Oral Presentation Titled Transforming Anabolic Treatments For Osteoporosis: Reports Phase 1 Data Showing Single-Tablet EB613 Matches Forteo PK/PD Profile
Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today reported comparative Phase 1 data evaluating single-tablet and multi-tablet oral EB613 with Forteo® (teriparatide SC injection, Eli Lilly). The oral presentation "Transforming Anabolic Trea...
06-15 20:50
Entera Bio Announces Presentations Of New Data Supporting Its Oral Peptide Pipeline At The Annual Endochrine Society Meeting On June 13-16
Abstract Title: Transforming Anabolic Treatments for Osteoporosis: New Clinical Data Supports a Single EB613 Tablet [Oral PTH(1-34)] as the Final Candidate for a Phase 3 StudySession Title: Late-Breaking Oral
05-28 20:54
Entera Bio Faces Elevated Operational Risks Amid Escalating Middle East Geopolitical Tensions
Entera Bio (ENTX) has disclosed a new risk, in the Economy & Political Envi...
05-10 14:01
Entera Bio Highlights Q1 2026 Progress and Financing
Entera Bio ( ($ENTX) ) has issued an update. Entera Bio reported first-quarter ...
05-09 04:53
Entera Bio Q1 EPS $(0.07) Beats $(0.08) Estimate
Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 16.67 percent decrease over losses of $(0.06) per share from the
05-09 04:06
